Pharma Marketing Network

Pharma marketers often invest heavily in biomarker awareness, genomic testing education, and precision medicine campaigns. Yet one of the biggest barriers may appear before a physician ever orders a test. A clinician recognizes concerning symptoms, considers several possibilities, and decides to wait rather than pursue advanced testing. A strategy for addressing diagnostic in...

A prescription is no longer the finish line for an infused specialty therapy. Increasingly, where a patient can receive treatment determines whether therapy starts smoothly, gets delayed, or is abandoned. Payer policies, provider capacity, costs, and patient needs can all influence that destination. As a result, specialty pharma brands increasingly need a marketing st...

Most pharmaceutical marketing budgets are built months before the market conditions they are supposed to address actually unfold. By the second quarter, a competitor may have launched, payer coverage may have shifted, new clinical evidence may have emerged, or regulatory developments may have changed a brand’s priorities.

Yet the budget often remains locked to assumpti...

Years of regulatory caution, category conventions, and competitive imitation have created a strange problem in pharmaceutical marketing: too many campaigns are becoming difficult to tell apart. The same visual language appears. The same claims lead the story. Even the same reassuring tone follows audiences from one brand to another.

So, if everyone is communicating cre...

Pharmaceutical marketers spend a great deal of time watching competitors. They track new campaigns, messaging, channel investments, launches, and market share. However, what happens when every company is watching the same small group of rivals? A smarter approach to competitive benchmarking looks beyond direct competitors and asks a more useful question: Who is genuinely best...